Study identifier:RO-2455-401-DE
ClinicalTrials.gov identifier:NCT01285167
EudraCT identifier:N/A
CTIS identifier:N/A
Daxas for COPD therapy (DACOTA)
Chronic Obstructive Pulmonary Disease
-
No
Daxas
All
3645
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
DACOTA | Drug: Daxas 500 microgram, oral, once daily as add-on therapy to existing therapy |